- Details
- In this discussion, Alicia Morgans and Terence Friedlander discuss updates from the EV-103 study. The EV-103 study is a phase one/two clinical trial that looked at the combination of enfortumab vedotin and pembrolizumab in, previously treated, patients with cisplatin-ineligible, metastatic urothelial cancer. Historically, cisplatin-ineligible metastatic urothelial cancer patients have had a very p...
|
- Details
- Sean Sachdev and Praneet Polineni delve into their paper on trimodality therapy for muscle-invasive bladder cancer. Dr. Sachdev highlights the growing evidence supporting trimodality therapy as a viable option, especially for older patients who may not be good candidates for surgical intervention. Dr. Polineni offers details on their study, which involved 32 patients with a mean age of 73. The tre...
|
- Details
- Cisplatin chemotherapy is the standard of care for medically fit patients in advanced urothelial carcinoma. Unfortunately, up to 50% of these patients are medically ineligible for cisplatin due to low-performance status, renal dysfunction, or other medical comorbidities. Immune checkpoint blockade is a first-line therapeutic option in either platinum ineligible patients or carboplatin eligible pat...
|
- Details
- Several Phase III trials have read out in the first-line treatment of metastatic urothelial cancer in the past few years. In a discussion with Ashish Kamat, Matthew Galsky discusses the expanse in clinical data in metastatic urothelial cancer shaping the treatment landscape. Guiding this conversation, Matthew Galsky focuses on 4 main take-home points and shares optimism in potential development to...
|
- Details
- Alicia Morgans hosts a discussion with Neeraj Agarwal and Petros Grivas about the FDA's approval of sacituzumab govitecan for treating metastatic urothelial carcinoma. Dr. Grivas elaborates on the TROPHY-U-01 trial that led to the drug's approval, emphasizing its efficacy in a heavily pretreated patient population with poor prognostic factors. He notes an overall response rate of 27% and manageabl...
|
- Details
- A transurethral resection of bladder tumor (TURBT), followed by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) is a standard-of-care therapy for muscle-invasive bladder cancer (MIBC). Andrea Necchi, a medical oncologist, and Ewan Gibb a researcher at Decipher Biosciences join Alicia Morgans to discuss a study that expands our understanding of the biology of pembrolizumab-resistant musc...
|
- Details
- Alicia Morgans talks with Andrea Necchi and Laura Marandino. They delve into the PURE-01 study, which focuses on the use of neoadjuvant pembrolizumab in muscle-invasive bladder cancer patients. Dr. Necchi elaborates on the study's primary and secondary endpoints and highlights the role of PET-CT imaging in assessing treatment response. The study finds that PET-CT has limited utility in predicting...
|
- Details
- Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% with a median overall survival (OS) of 7-8 months. Sacituzumab govitecan (Trodelvy) is a TROP-2–directed antibody-drug conjugate with an SN-38 payload that has shown pr...
|
- Details
- Alicia Morgans speaks with Petros Grivas to discuss the intricacies of the SWOG 1806 clinical trial, led by Dr. Parminder Singh. This multi-institutional study aims to evaluate the efficacy of adding atezolizumab, an anti-PD-L1 agent, to chemoradiation treatment in patients with localized muscle-invasive urothelial carcinoma. Dr. Grivas emphasizes the collaborative nature of this "Herculean effort...
|
- Details
- Alicia Morgans is joined by Petros Grivas to discuss a unique study focusing on patients with variant histologies of bladder cancer. The study aims to improve complete response rates by combining chemotherapy with pembrolizumab in a neoadjuvant setting. With only 17 patients, it's a pilot study that tackles the difficulty in finding effective treatments for varying histologies such as squamous cel...
|
